Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

Summary

This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or relapsed/refractory CD20-positive non-Hodgkin lymphoma (NHL). The primary endpoint of the study is to determine the maximum tolerated dose (MTD) of NAM-NK cells while maintaining safety.

Timeline

Start

2017-10-18

Primary completion

2022-08-15

Completion

2022-08-15

Publications

• Cichocki F, Zhang B, Wu CY, Chiu E, Day A, O'Connor RS, Yackoubov D, Simantov R, McKenna DH, Cao Q, Defor TE, Janakiram M, Wangen R, Cayci Z, Snyder N, Kumar A, Grzywacz B, Hwang J, Geffen Y, Miller JS, Maakaron J, Bachanova V. Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma. Sci Transl Med. 2023 Jul 19;15(705):eade3341. doi: 10.1126/scitranslmed.ade3341. Epub 2023 Jul 19.

Drugs

Indications